Last reviewed · How we verify
A Phase 2a Trial Evaluating the Anti-psoriatic Effect of LP0113 Aerosol Spray Compared With Its Vehicle and With Daivobet® Gel, LEO 90100 Aerosol Foam, Betamethasone Dipropionate Aerosol Spray and Calcipotriol Aerosol Spray in the Treatment of Psoriasis Vulgaris (LP0113-1123)
The purpose of this study is to evaluate the anti-psoriatic effect of LP0113 aerosol spray compared to Daivobet® gel, LEO 90100 aerosol foam, betamethasone dipropionate in the aerosol spray vehicle, calcipotriol in the aerosol spray vehicle and aerosol spray vehicle.
Details
| Lead sponsor | LEO Pharma |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 50 |
| Start date | 2015-04 |
| Completion | 2015-06 |
Conditions
- Skin and Connective Tissue Diseases
Interventions
- LP0113 aerosol spray
- Aerosol spray vehicle
- LEO 90100 aerosol foam
- Betamethasone dipropionate aerosol spray
- Calcipotriol aerosol spray
- Daivobet® gel
Primary outcomes
- Absolute change in Total Clinical Score (TCS) of clinical signs (sum of erythema, scaling and infiltration) — End of treatment compared to baseline - 4 weeks
Countries
France